Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
NCT06207071
Recruiting
Growth-restricted very preterm infants (VPT) are born without adequate fat mass (FM) deposits and low docosahexaenoic acid (DHA) concentrations. They often experience further declines in DHA concentrations during the initial three weeks post-birth while advancing enteral feeds and receiving lipid supplementation predominantly through parenteral nutrition. These suboptimal enteral and parenteral nutrition practices significantly heighten the risk of faltering postnatal growth. One promising appro... Read More
Gender:
ALL
Ages:
Between 24 hours and 72 hours
Trial Updated:
05/26/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Infant Malnutrition, Light-For-Dates With Signs of Fetal Malnutrition, Premature, Nutrition Disorder, Infant
Register for Updates
COES: Curing Order Effects on Sealants
NCT06342258
Recruiting
Background: Sealants are a great tool in the prevention of caries in the pediatric population. It has been shown that up to 71% of occlusal decay is preventable after a single sealant application in a fissure, and thus is the standard of care due to difficulty for pediatric patients in hygiene, diet, and overall home care until manual dexterity increases. Purpose: This prospective randomized case control study aims to look at the longevity of sealants with bonding agent cured prior to sealant p... Read More
Gender:
ALL
Ages:
Between 5 years and 14 years
Trial Updated:
05/26/2025
Locations: Herman Ostrow School of Dentistry of USC, Los Angeles, California
Conditions: Dental Sealant, Sealant Retention
Register for Updates
Correlation Between Noninvasive Blood Vessel Functionality Parameters and Cerebral Hemodynamics in Neurocritical Care Patients
NCT06511804
Recruiting
The purpose of this clinical research project is to employ Mespere LifeSciences NeurOs Cerebral Oximetry system, equipped with noninvasive sensors approved by the FDA, to monitor and investigate the correlation within a cohort of patients suffering from traumatic brain injury (TBI), stroke, brain tumor, and brain bleeding. This study aims to investigate and establish the correlation between blood vessel functionality parameters-specifically, Vasodilation/Constriction Index (VDC), Vascular Resist... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/26/2025
Locations: University of Louisville Health, Louisville, Kentucky
Conditions: Brain Injuries, Intracranial Pressure Increase, Monitoring
Register for Updates
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
NCT06667687
Recruiting
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed. ABBV-291 is an investigational dr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Carolina BioOncology Institute /ID# 265259, Huntersville, North Carolina +9 locations
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
Efficacy and Safety of Leadless Pacemakers Versus Left Bundle Area Pacing - A Preliminary Exploration
NCT06690333
Recruiting
This is a prospective, randomized controlled (1:1) multicenter trial. The pilot study will be conducted up to three clinical sites in the United States. The primary purpose of this study is to compare the overall safety and efficacy between the leadless pacemaker and left bundle area pacing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: NCH Healthcare, Naples, Florida +1 locations
Conditions: Pacemaker Implantation, AV Node Disease
Register for Updates
A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms
NCT06693648
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 6-week trial of a formulation of AMZ001 once daily versus placebo once daily.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
05/26/2025
Locations: Millennium Clinical Trials, Thousand Oaks, California +10 locations
Conditions: Osteoarthritis of Knee, Osteoarthritis, Knee
Register for Updates
Early Detection of Vaping-related Vascular Diseases
NCT05454267
Recruiting
The purpose of this study is to determine how vaping affects blood vessels, in particular if early damage occurs in the lung vessels.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
05/25/2025
Locations: University of Miami Health System, Miami, Florida
Conditions: Vaping, Blood Vessel Injury
Register for Updates
A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System
NCT06147336
Recruiting
The objective of this study is to evaluate the safety and performance of the V-LAP System in subjects with New York Heart Association (NYHA) functional class II and III HF, irrespective of left ventricular ejection fraction.
Gender:
ALL
Ages:
Between 22 years and 88 years
Trial Updated:
05/25/2025
Locations: One Boston Medical Center Place, Boston, Massachusetts
Conditions: Heart Failure
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07002905
Recruiting
This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/25/2025
Locations: Ascletis Clinical Site, Rogers, Arkansas +5 locations
Conditions: Chronic Weight Management
Register for Updates
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
NCT00209235
Recruiting
We, the researchers, are following the natural history of Albright hereditary osteodystrophy. We have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1A, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1A typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evalua... Read More
Gender:
ALL
Ages:
Between 2 months and 89 years
Trial Updated:
05/23/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy, Pseudopseudohypoparathyroidism
Register for Updates
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489
Recruiting
This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.
Gender:
ALL
Ages:
All
Trial Updated:
05/23/2025
Locations: Clinical Trial Site, Phoenix, Arizona +103 locations
Conditions: Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, LIPA Deficiency, LAL-Deficiency
Register for Updates
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
NCT03407469
Recruiting
The goal of this research study is to learn about the quality of life, experiences with treatment, and healthcare costs of patients who are receiving long-term treatment for venous thromboembolism (VTE) that is related to cancer. This is an investigational study. Up to 260 participants will be enrolled in this multicenter study. Up to 170 will take part in MD Anderson.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas +3 locations
Conditions: Cancer-related Venous Thromboembolism
Register for Updates